Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at University West, has received support from the national drug discovery platform at Scilife LAB. The lead candidates have shown strong potential, particularly for severe infections like chronic urinary tract and lung infections.With the help of DDD, they will focus on optimizing these compounds to meet industry standards. Bringing them closer to clinical use as a much-needed alternative for life-threatening infections. The current project is going very well and we have alreday treached some very promising improved pre-CD molecules and hope to be able to nominate or CD in mid 2026.
Lead optimisation support from Scilife DDD
Latest in News and Publications
AMR Conference Basel – 2026
Inicure particppated in the AMR conference i Basel meeting research collaborators, service providers and potential future commercial partners
INCATE – Network and Support
Inicure has been awarded support from the INCATE network (Incubator for Antibacterial Therapies in Europe). Access to advice and
Seal of Excellence – EIC – Transition proposal iCURE
The EIC-Transition proposal — iCURE “Novel small molecule FPR1 agonists for treating antibiotic-resistant and chronic bacterial infections” coordinated




